Onxeo S.A. | Mutual Funds
Mutual Funds that own Onxeo S.A.
DFA Continental Small Company Series
295,277
0.57%
0
0.01%
01/31/2018
Generali Ambition
200,000
0.39%
126,875
0.14%
12/30/2016
LBPAM Actions Santé
160,082
0.31%
0
0.14%
06/29/2018
DFA International Core Equity Portfolio
125,126
0.25%
18,764
0%
04/30/2018
Actys 3
58,136
0.11%
0
0.25%
06/29/2018
GF Europe
56,250
0.11%
0
0.2%
12/30/2016
SPDR S&P World (ex-US) ETF
47,990
0.09%
186
0%
09/06/2018
45,713
0.09%
23,932
0.12%
08/31/2018
Danske Invest Danmark Indeks Small Cap
45,713
0.09%
23,932
0.12%
08/31/2018
Actys 1
34,823
0.07%
0
0.13%
06/29/2018
| Address |
49, blvd. du Général Martial Valin
Paris Ile-de-France 75015
France
|
|
Employees
|
- |
| Website |
http://www.onxeo.com |
| Updated |
07/08/2019 |
| Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA. The company was founded by Gilles Avenard and Dominique Costantini on March 5, 1997 and is headquartered in Paris, France. |
